Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
André VoelzmannSchool of Environmental and Life Sciences, Faculty of Science and Engineering, University of Hull, Hull HU6 7RX, United Kingdom.ORCID 0000-0002-7682-5637
Lubna Nuhu-SosoYork Biomedical Research Institute and Department of Biology, University of York, York YO10 5DD, United Kingdom.ORCID 0000-0002-5244-2666
Alex E RoofYork Biomedical Research Institute and Department of Biology, University of York, York YO10 5DD, United Kingdom.
Sanjai PatelManchester Fly Facility, Faculty of Biology, Medicine and Health, School of Biological Sciences, University of Manchester, Manchester M13 9PL, United Kingdom.
Hayley BennettGenome Editing unit, Faculty of Biology, Medicine and Health, School of Biological Sciences, University of Manchester, Manchester M13 9PL, United Kingdom.
Antony AdamsonGenome Editing unit, Faculty of Biology, Medicine and Health, School of Biological Sciences, University of Manchester, Manchester M13 9PL, United Kingdom.ORCID 0000-0002-5408-0013
Gareth J O EvansYork Biomedical Research Institute and Department of Biology, University of York, York YO10 5DD, United Kingdom.ORCID 0000-0003-2573-7001
Marvin BentleyDepartment of Biological Sciences and the Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180.ORCID 0000-0002-1754-0332
Ines HahnManchester Academic Health Science Centre, Faculty of Biology, Medicine and Health, Division of Molecular and Cellular Function, School of Biological Sciences, University of Manchester, Manchester M13 9PL, United Kingdom.ORCID 0000-0001-7703-8160
Funding
Mechanisms of vesicle trafficking and kinesin regulationR35GM153259 · NIGMS · RENSSELAER POLYTECHNIC INSTITUTE · PI Marvin Bentley · 2024 to 2026
$1.2M
Academy of Medical Sciences (The Academy of Medical Sciences) SBF008\1140HHS | NIH (NIH) R35GM153259Leverhulme Trust (The Leverhulme Trust) ECF-2017-247NIGMS NIH HHS R35 GM153259Royal Society (The Royal Society) RGS\R2\222151UKRI | Biotechnology and Biological Sciences Research Council (BBSRC) UKRI1894Wellcome Trust (WT) 087742/Z/08/Z
6 · The paper itself
Abstract
Glycogen Synthase Kinase 3β (GSK-3β) is a key coordinator of neuronal development and maintenance; hyperactive GSK-3β is linked to neurodevelopmental and -degenerative diseases and therefore a promising therapeutic target. In neurons, GSK-3β coordinates the cytoskeleton by phosphorylating microtubule-binding proteins. In this study, we found that tight regulation of GSK-3β kinase activity is required for the maintenance of parallel microtubule bundles in
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
GSK-3β coordinates axonal microtubule organization through Shot and Tau. · full record | OpenQuestion